Clonal hematopoiesis in myeloma: root of all maladies!

Abstract

In this issue of Blood, Maia et al investigate the sequelae and clinical significance of dysplastic hematopoiesis at time of diagnosis in patients with multiple myeloma (MM). By performing multidimensional flow cytometry (MFC) to prospectively screen for the presence of myelodysplastic syndrome (MDS)associated phenotypic alterations (MDS-PA) and clonal hematopoiesis (CH) in bone marrow samples of newly diagnosed MM patients (NDMM), the authors support the use of cost-effective MFC as a screening method to identify dysplasia in patients with NDMM.1